顽固性高血压的生活管理方式
Lifestyle Management of Refractory Hypertension
DOI: 10.12677/ACM.2024.141103, PDF, HTML, XML, 下载: 84  浏览: 129 
作者: 李成香:西海岸新区人民医院心内科,山东 青岛
关键词: 顽固性高血压血压危险因素Resistant Arterial Hypertension Blood Pressure Risk Factors
摘要: 目的:本综述旨在描述顽固性动脉高血压(RAH)的定义和患病率、与难治性高血压之间的区别、患者特征和RAH的主要危险因素、如何诊断RAH、患者的预后和结果。材料和方法:根据世界卫生组织的数据,全世界约有12.8亿30~79岁的成年人患有动脉高血压,其中超过80%的人血压(BP)未得到控制。RAH被定义为尽管同时使用3种或更多类抗高血压药物,但血压仍高于目标值,通常包括长效钙通道阻滞剂、肾素–血管紧张素系统抑制剂(血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂)和噻嗪类利尿剂以最大或最大耐受剂量和适当的给药频率给药。RAH发生在6名高血压患者中的近1名。它常常未被识别,主要是因为尽管血压未得到控制,但患者并未开出≥3种最大剂量的药物。结论:RAH明显增加患冠状动脉疾病、心力衰竭、中风和慢性肾病的风险,并导致更高的主要心血管不良事件发生率以及全因死亡率增加。及时诊断和治疗RAH可以减轻相关风险并改善短期和长期预后。
Abstract: Purpose: The current review is to describe the definition and prevalence of resistant arterial hy-pertension (RAH), the difference between RAH and refractory hypertension, patient characteristics and major risk factors for RAH, how RAH is diagnosed, prognosis and outcomes for patients. Materi-als and Methods: According to the WHO, approximately 1.28 billion adults aged 30~79 worldwide have arterial hypertension, and over 80% of them do not have blood pressure (BP) under control. RAH is defined as above-goal elevated BP despite the concurrent use of 3 or more classes of antihy-pertensive drugs, commonly including a long-acting calcium channel blocker, an inhibitor of the renin-angiotensin system (angiotensin-converting enzyme inhibitor or angiotensin receptor block-er), and a thiazide diuretic administered at maximum or maximally tolerated doses and at appro-priate dosing frequency. RAH occurs in nearly 1 of 6 hypertensive patients. It often remains unrec-ognised mainly because patients are not prescribed ≥3 drugs at maximal doses despite uncon-trolled BP. Conclusion: RAH distinctly increases the risk of developing coronary artery disease, heart failure, stroke and chronic kidney disease and confers higher rates of major adverse cardio-vascular events as well as increased all-cause mortality. Timely diagnosis and treatment of RAH may mitigate the associated risks and improve short and long-term prognosis.
文章引用:李成香. 顽固性高血压的生活管理方式[J]. 临床医学进展, 2024, 14(1): 741-747. https://doi.org/10.12677/ACM.2024.141103

1. 介绍

顽固性动脉高血压是一种严重的疾病,会导致严重的心血管并发症,如心脏病发作、中风和死亡。它被定义为尽管同时使用3种或更多类别的抗高血压药物,并且以最大耐受剂量和适当的给药频率给药,血压仍高于目标值。在诊断顽固性动脉高血压之前,必须排除不坚持服用抗高血压药物的情况。并且应当适当测量血压。测量血压前,应坐在舒适的椅子上,背部有支撑,双脚平放在地面上,双腿不交叉至少5分钟。袖带长度应至少为臂围的80%,宽度至少为臂围的40%。将袖带直接放在上臂皮肤上,位于心脏水平处。获取3个读数,间隔1分钟。丢弃第一次读数并取第二次和第三次读数的平均值。难治性动脉高血压应与难治性高血压相区别,难治性高血压是在用5种或更多不同类别的抗高血压药物的最大或接近最大治疗后血压仍未得到控制的情况。

2. 难治性动脉高血压的定义

难治性动脉高血压(RAH)是一种高风险疾病,会导致心脏结构受损并增加死亡率 [1] 。它被定义为尽管同时使用3类或更多类抗高血压药物(通常包括长效降压药物),但血压(BP)仍高于目标值 [1] 。药物包括钙通道阻滞剂、肾素–血管紧张素系统抑制剂(血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂[ARB])和噻嗪类利尿剂。所有药物均应以最大或最大耐受剂量和适当的给药频率给药 [2] 。具有白大衣效应的患者以及那些不符合RAH诊断的患者不应纳入RAH的定义中 [3] 。

3. 血压测量和技术的错误

血压测量的错误可能导致RAH的误诊。血压测量结果通常取决于患者的准备、环境条件、袖带尺寸和测量技术,需要在至少两个不同的场合获得至少两个读数的平均值 [2] [4] 。诊室外血压和自我监测血压需要适当的技术才能获得准确的血压结果 [5] [6] 。一项研究将临床工作人员的标准分诊血压测量值与自动设备进行比较,在患者无人监管并坐在安静的房间中时,自动设备最多可获取6次血压测量值(间隔1分钟),结果显示,33%的RAH患者血压测量值不准确 [7] 。患有严重动脉疾病和动脉僵硬、钙化的患者可能会出现袖带压力不适当升高的情况,这种情况称为假性高血压。正确的血压测量技术包括通过排空充盈的膀胱,双腿不交叉并以背部、手臂和脚支撑的方式坐在安静的房间中,同时个人做好准备,选择袖带长度至少为臂围80%、宽度至少为臂围40%的血压袖带,将袖带直接放在上臂皮肤上,位于支撑臂上心脏的高度,获得间隔1分钟的三个读数。丢弃第一次读数并取第二次和第三次读数的平均值。

4. 白大衣效果

“白大衣效应”被定义为对临床就诊的不适当的血压反应,但对于具体如何定义尚未达成一致。最广泛使用的定义是平均门诊测量值和日间动态测量值之间的血压差异。与Mancia等人之前的观察相反。最近研究表明,与血压控制良好的高血压患者相比,无器官损害的白大衣高血压患者发生CVD并发症的风险更高。为了排除真正的RAH,通常需要进行诊室外血压监测。白大衣效应归因于医疗保健提供者或诊所环境触发的警报反射,激活了交感神经系统 [8] 。通过诊室血压测量发现,28%至39%的aTRAH患者可能出现临床上显着的白大衣效应 [9] 。德拉塞拉等人研究发现,在西班牙动态血压监测登记处纳入的超过8200名明显RAH患者中,62.5%被归类为真正的RAH,而其余37.5%被确定为白大衣高血压。

5. 药物不依从

在诊断RAH之前,还必须排除不坚持服用抗高血压药物的情况。在患有较严重高血压的患者中,不坚持用药是很常见的 [10] 。大约50%~80%的高血压患者表现出对抗高血压药物的依从性不佳。原因有药物经济负担大、给药复杂性、多药抗高血压治疗方案不良反应频率高、患者与临床医生关系不佳以及临床医生惰性有关。一些系统评价和荟萃分析评估了干预措施(包括抗高血压治疗的修改)对抗高血压药物依从性的影响 [11] 。因此,在高血压患者中,与自由药物联合方案相比,固定剂量联合方案可将不依从用药的风险降低24%。最近发表的荟萃分析(15名RCI和7415名参与者)表明,与常规护理或最小干预相比,行为自我监测干预措施与医生建议相结合,导致收缩压和舒张压(DBP)发生更高且显著的变化。

6. RAH与难治性高血压

难治性高血压是指使用五种或更多不同类别的抗高血压药物(包括长效噻嗪类利尿剂(如氯噻酮)和盐皮质激素拮抗剂)进行最大或接近最大治疗后血压仍未得到控制的病症 [12] 。RAH通常可以通过调整治疗得到控制。相比之下,尽管巧妙地尝试使用协同抗高血压药物,难治性高血压通常仍无法得到控制 [12] 。

7. 全球难治性动脉高血压的患病率(按人口统计)

在接受治疗的高血压成人中,RAH的发生率约为12%~15%的人群和15%~18%的临床报告 [13] ,主要发生在有长期高血压和慢性肾病(CKD)病史的患者中。在基于人群和临床的研究中,一些RAH病因可能仍未被完全发现,因为尽管血压不受控制,但患者并未以最大剂量服用3种药物。相比之下,临床试验通常包括强制滴定方案,通过减少次优治疗的发生率来揭示RAH [14] 。RAH的人口统计学相关因素包括黑人种族、老年和男性。RAH的特点是不同的人口统计学、合并症、生理异常和代谢异常。然而,这些因素并不相互排斥,因为事实上,它们可以基本上相互依赖(例如,非下降或反向下降血压和交感神经系统过度活跃、内脏肥胖和醛固酮分泌过多)。

8. RAH患者的特征

8.1. 肥胖

NHANES (国家健康和营养检查调查)对13,375名成人高血压患者的调查结果表明,体重指数(BMI) 30 kg/m [2] 会使患aTRH风险增加一倍 [15] 。西班牙14,461名RAH患者动态血压监测登记处显示,BMI 30 kg/m [2] 也是RAH的独立危险因素(比值比,1.62;95% CI 1.32~1.99)。在3367名患有慢性肾病(CKD)的高血压患者中,肥胖水平的增加与aTRH的较高风险独立相关,优势比范围为1.52 (BMI 30 kg/m [2] )至2.26 (BMI 40 kg/m [2] )。

8.2. 钠

膳食钠摄入量较高与动脉血压升高独立相关 [16] 。然而,血压的“盐敏感性”存在较大的个体间和种族差异。这会导致容量滞留过多、血管功能障碍、动脉僵硬、交感神经激活、肾素–血管紧张素轴抑制受损、盐皮质激素受体激活和免疫细胞调节。几项研究表明,低钠饮食后RAH患者的血压显着降低 [17] 。

8.3. 缺乏身体活动

体力活动减少和体能下降都是高血压的独立危险因素 [18] 。REGARDS队列中患者自我报告的不活动并不能预测RAH。相反,在50名接受治疗的RAH患者中,每周三次的跑步机步行锻炼计划持续8~12周显着降低了日间动态血压(6 ± 12/3 ± 7 mmHg; p = 0.03)。

8.4. 酒精摄入量

酒精摄入与血压升高和患高血压的风险有关 [19] 。男性和女性之间的剂量反应关联可能有所不同,并受到代谢基因的影响 [20] 。饮酒量 > 30~50克/天是高血压的独立危险因素。

8.5. 焦虑和抑郁

在全球范围内,高达33.7%的人口在一生中患有焦虑症 [21] 。在八项前瞻性研究的系统回顾和荟萃分析中 [22] ,基线焦虑增加了高血压发生的风险,汇总调整后的HR为1.55 (95% CI 1.24~1.94),检测到很强的异质性(PQ < 0.001; 1/4 84.6%)。最近的研究表明共病焦虑与RAH之间呈正相关。特别是,与健康对照和非难治性高血压患者相比,RAH患者在贝克抑郁量表(5分)和汉密尔顿焦虑量表(3分)中得分更高。抑郁会对高血压病程产生负面影响,干扰药物的依从性。

8.6. 自然灾害、灾难、战争

精神和身体压力、失眠、因食用储存食物而摄入过量盐以及感染(肺炎)是自然灾害、灾难和战争期间高血压的主要原因 [23] 。高血压相关疾病在灾害发生后立即发生,其风险持续到生活环境稳定和生活习惯改善为止。血压升高和血压升高持续时间存在较大的个体差异。因此,据报道,地震发生后2~4周内收缩压平均增加5~25 mmHg。民意调查欧洲健康、老龄化和退休研究所(SHARE)证明,童年时期经历战争与心血管疾病、糖尿病、高胆固醇和高血压的终生风险增加相关 [24] 。

8.7. 病人合并症

多种合并症与RAH相关。如肥胖、左心室肥厚、蛋白尿、糖尿病、CKD、阻塞性睡眠呼吸暂停(OSA) [25] 。RAH患者中很大一部分(60% ± 84%)患有睡眠呼吸暂停。其他睡眠异常也出现在RAH中(相对于高血压得到控制或血压正常的患者),包括睡眠时间较短、睡眠效率降低和快速眼动睡眠较少。

8.8. 生理紊乱

RAH的生理异常包括血管疾病/功能障碍,表现为外周动脉粥样硬化率高和颈动脉粥样硬化、内皮功能受损 [26] 、动脉顺应性降低和全身血管阻力升高,所有这些与非RAH相比,RAH中这一现象更为明显。大部分(43% ± 65%) RAH患者的正常夜间血压下降也有所减弱。

8.9. 代谢紊乱

RAH还与代谢紊乱有关,包括高尿酸血症醛固酮过量和循环肾素水平抑制相关 [27] 。一般来说,RAH的特点是BP具有高度的盐敏感性。将膳食钠摄入量减少到显着低于西方社会通常摄入量的水平(例如50 mmol/天)可以迅速且显着地降低许多RAH患者的血压。

8.10. 遗传变异

一些基于家庭的研究显示了RAH的遗传性,表明50%~60%的血压变异可归因于遗传因素 [28] 。大多数RAH的遗传学研究都有显着的局限性,例如样本量不足。

9. 难治性动脉高血压的预后和结果

在一项对超过200,000名新发高血压患者的回顾性研究中,在中位3.8年的随访中,患有RAH的患者出现死亡、心肌梗塞、心力衰竭、中风或CKD等综合结果的可能性高出47% [29] 。在一项超过400,000名参与者的研究中,RAH患者患终末期肾病的风险增加32%,缺血性心脏事件的风险增加24%,心力衰竭的风险增加46%,发生心力衰竭的风险增加14%与没有RAH的患者相比,中风的发生率和死亡风险增加6%。使用动态血压监测的前瞻性研究表明,与治疗有效的高血压患者相比,真正的RAH患者发生CVD事件的风险几乎增加了2倍。

RAH与患有某些合并症的患者预后较差有关。因此,在冠状动脉疾病患者中,RAH与主要不良心血管事件(MACE;即心血管死亡、心肌梗死和中风)的发生率较高相关。在CKD患者中,与无RAH的患者相比,RAH与心肌梗死、中风、外周动脉疾病、心力衰竭和全因死亡率的风险较高相关 [30] 。相反,RAH与射血分数降低的心力衰竭患者的不良临床事件增加无关,并且可能降低心力衰竭相关的再住院风险。

9.1. 进一步药物治疗

根据最近的指南,尽管存在常见的剂量限制性不良反应,但仍建议将螺内酯(一种盐皮质激素受体拮抗剂)作为四线药物处方 [31] 。最近发表的Baxdrostat治疗难治性高血压的2期临床试验显示,在难治性高血压患者中,2、1、0.5 mg Baxdrostat观察到收缩压出现剂量依赖性变化,分别为20.3、17.5、12.1 mmHg。Baxdrostat是一种选择性醛固酮合酶抑制剂,可能是治疗耐药的原因之一。

抑制激素合成而不是通过阻断盐皮质激素受体。临床前和一期研究表明,与皮质醇合成所需的酶11b-羟化酶相比,baxdrostat对醛固酮合酶具有较高的选择性(选择性比为100:1),11b-羟化酶与醛固酮合酶具有93%的序列相似性 [32] 。

9.2. 结论

RAH是一种严重的疾病,与没有RAH的患者相比,患者发生终末期肾病、主要不良心血管事件、中风、心力衰竭和全因死亡率的风险显著增加。及时诊断RAH将有助于及时采取预防和治疗干预措施,以减轻RAH相关后果。

参考文献

[1] Acelajado, M.C., Hughes, Z.H., Oparil, S. and Calhoun, D.A. (2019) Treatment of Resistant and Refractory Hyperten-sion. Circulation Research, 124, 1061-1070.
https://doi.org/10.1161/CIRCRESAHA.118.312156
[2] Whelton, P.K., Carey, R.M., Aronow, W.S., et al. (2017) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/-ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clini-cal Practice Guidelines. Hypertension, 71, 1269-1324.
https://doi.org/10.1161/HYP.0000000000000066
[3] Carey, R.M., Calhoun, D.A., Bakris, G.L., et al. (2018) Re-sistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement from the American Heart Associa-tion. Hypertension, 72, E53-E90.
[4] Pickering, T.G., Hall, J.E., Appel, L.J., et al. (2005) Recommendations for Blood Pressure Measurement in Humans and Experimental Animals: Part 1: Blood Pressure Measurement in Humans: A Statement for Professionals from the Subcommittee of Professional and Public Education of the American Heart Associa-tion Council on High Blood Pressure Research. Circulation, 111, 697-716.
https://doi.org/10.1161/01.CIR.0000154900.76284.F6
[5] Calhoun, D.A., Jones, D., Textor, S., et al. (2008) Re-sistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 51, 1403-1419.
https://doi.org/10.1161/HYPERTENSIONAHA.108.189141
[6] Parati, G., Stergiou, G.S., Asmar, R., et al. (2010) European Society of Hypertension Practice Guidelines for Home Blood Pressure Monitoring. Journal of Human Hypertension, 24, 779-785.
https://doi.org/10.1038/jhh.2010.54
[7] Bhatt, H., Siddiqui, M., Judd, E., Oparil, S. and Calhoun, D. (2016) Prevalence of Pseudoresistant Hypertension due to Inaccurate Blood Pressure Measurement. Journal of the American Society of Hypertension, 10, 493-499.
https://doi.org/10.1016/j.jash.2016.03.186
[8] Messerli, F.H., Ventura, H.O. and Amodeo, C. (1985) Osler’s Maneuver and Pseudohypertension. The New England Journal of Medicine, 312, 1548-1551.
https://doi.org/10.1056/NEJM198506133122405
[9] Whelton, P.K., Carey, R.M., Aronow, W.S., et al. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ -ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiolo-gy/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiol-ogy, 71, e127-e248.
https://doi.org/10.1016/j.jacc.2017.11.006
[10] Mancia, G., Facchetti, R., Vanoli, J., et al. (2022) White-Coat Hypertension without Organ Damage: Impact on Long- Term Mortality, New Hypertension, and New Organ Damage. Hypertension, 79, 1057-1066.
https://doi.org/10.1161/HYPERTENSIONAHA.121.18792
[11] Grassi, G., Turri, C., Vailati, S., Dell’Oro, R. and Mancia, G. (1999) Muscle and Skin Sympathetic Nerve Traffic during the ‘White-Coat’ Effect. Circulation, 100, 222-225.
https://doi.org/10.1161/01.CIR.100.3.222
[12] Salles, G.F., Cardoso, C.R.L. and Muxfeldt, E.S. (2008) Prognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension. Archives of Internal Medi-cine, 168, 2340-2346.
https://doi.org/10.1001/archinte.168.21.2340
[13] de la Sierra, A., Segura, J., Banegas, J.R., et al. (2011) Clinical Features of 8295 Patients with Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension, 57, 898-902.
https://doi.org/10.1161/HYPERTENSIONAHA.110.168948
[14] Hameed, M.A., Tebbit, L., Jacques, N., Thomas, M. and Dasgupta, I. (2016) Non-Adherence to Antihypertensive Medication Is Very Common among Resistant Hyper-tensives: Results of a Directly Observed Therapy Clinic. Journal of Human Hypertension, 30, 83-89.
https://doi.org/10.1038/jhh.2015.38
[15] Schulz, M., Krueger, K., Schuessel, K., et al. (2016) Medication Adher-ence and Persistence according to Different Antihypertensive Drug Classes: A Retrospective Cohort Study of 255,500 Patients. International Journal of Cardiology, 220, 668-676.
https://doi.org/10.1016/j.ijcard.2016.06.263
[16] Elliott, W.J. (2008) What Factors Contribute to the Inadequate Control of Elevated Blood Pressure? The Journal of Clinical Hypertension, 10, 20-26.
https://doi.org/10.1111/j.1524-6175.2007.08028.x
[17] Abegaz, T.M., Shehab, A., Gebreyohannes, E.A., et al. (2017) Nonadherence to Antihypertensive Drugs: A Systematic Review and Meta-Analysis. Medicine, 96, e5641.
https://doi.org/10.1097/MD.0000000000005641
[18] Nieuwlaat, R., Wilczynski, N., Navarro, T., et al. (2014) In-terventions for Enhancing Medication Adherence. Cochrane Database of Systematic Reviews, 2014, CD000011.
https://doi.org/10.1002/14651858.CD000011.pub4
[19] Hyman, D.J. and Pavlik, V. (2015) Medication Adherence and Resistant Hypertension. Journal of Human Hypertension, 29, 213-218.
https://doi.org/10.1038/jhh.2014.73
[20] Bangalore, S., Kamalakkannan, G., Parkar, S. and Messerli, F.H. (2007) Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. The American Journal of Medicine, 120, 713-719.
https://doi.org/10.1016/j.amjmed.2006.08.033
[21] Kassavou, A., Wang, M., Mirzaei, V., et al. (2022) The Asso-ciation between Smartphone App-Based Self-Monitoring of Hypertension-Related Behaviors and Reductions in High Blood Pressure: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth, 10, e34767.
https://doi.org/10.2196/34767
[22] Borghi, C., Tubach, F., De Backer, G., et al. (2016) Lack of Control of Hyper-tension in Primary Cardiovascular Disease Prevention in Europe: Results from the EURIKA Study. The American Jour-nal of Medicine, 218, 83-88.
https://doi.org/10.1016/j.ijcard.2016.05.044
[23] de la Sierra, A., Segura, J., Banegas, J.R., et al. (2022) Clinical Features of 8295 Patients with Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Exp.
https://pubmed.ncbi.nlm.nih.gov/?term=longqueryec1bd4807d9e18d38fb3
[24] Thomas, G., Xie, D., Chen, H.Y., CRIC Study Investigators, et al. (2016) Prevalence and Prognostic Significance of Apparent Treatment Resistant Hyper-tension in Chronic Kidney Disease: Report from the Chronic Renal Insufficiency Cohort Study. Hypertension, 67, 387-396.
https://doi.org/10.1161/HYPERTENSIONAHA.115.06487
[25] Shalaeva, E., Bano, A., Kasimov, U., et al. (2022) Coronary Artery Calcium Score and Coronary Computed Tomography Angiography Predict One-Year Mor-tality in Patients with Type 2 Diabetes and Peripheral Artery Disease Undergoing Partial Foot Amputation. Diabetes & Vascular Disease Research, 19, No. 5.
https://doi.org/10.1177/14791641221125190
[26] Egan, B.M., Zhao, Y., Li, J., et al. (2013) Prevalence of Optimal Treatment Regimens in Patients with Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network. Hypertension, 62, 691-697.
https://doi.org/10.1161/HYPERTENSIONAHA.113.01448
[27] Tanner, R.M., Calhoun, D.A., Bell, E.K., et al. (2013) Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD. Clinical Journal of the American Society of Nephrology, 8, 1583-1590.
https://doi.org/10.2215/CJN.00550113
[28] Smith, S.M., Huo, T., Delia Johnson, B., et al. (2014) Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women with Suspected Myocar-Dial Ischemia: A Report from the NHLBI-Sponsored WISE Study. Journal of the American Heart Association, 3, e000660.
https://doi.org/10.1161/JAHA.113.000660
[29] Sim, J.J., Bhandari, S.K., Shi, J., et al. (2013) Characteristics of Resistant Hypertension in a Large, Ethnically Diverse Hypertension Population of an Integrated Health System. Mayo Clinic Proceedings, 88, 1099-1107.
https://doi.org/10.1016/j.mayocp.2013.06.017
[30] Osborn, J.W. and Banek, C.T. (2018) Catheter-Based Renal Nerve Ablation as a Novel Hypertension Therapy: Lost, and Then Found, in Translation. Hypertension, 71, 383-388.
https://doi.org/10.1161/HYPERTENSIONAHA.117.08928
[31] Appel, L.J., American Society of Hypertension Writing Group, Giles, T.D., et al. (2009) ASH Position Paper: Dietary Approaches to Lower Blood Pressure. The Jour-nal of Clinical Hypertension, 11, 358-368.
https://doi.org/10.1111/j.1751-7176.2009.00136.x
[32] Saneei, P., Salehi-Abargouei, A., Esmaillzadeh, A. and Azadbakht, L. (2014) Influence of Dietary Approaches to Stop Hypertension (DASH) Diet on Blood Pressure: A Sys-tematic Review and Meta-Analysis on Randomized Controlled Trials. Nutrition, Metabolism and Cardiovascular Dis-eases, 24, 1253-1261.
https://doi.org/10.1016/j.numecd.2014.06.008